Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo tackles Hard-to-Treat myeloma

NCT ID NCT05646836

Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug (XmAb24306) combined with another drug (cevostamab) in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to check safety and find the right dose. About 90 participants will take part, and researchers will also monitor how well the drugs work against the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy of at least 12 weeks * Participants must have received a minimum of 3 prior lines of therapy, including at least one PI, one IMiD, and an anti-CD38 monoclonal antibody. * Documented evidence of progressive disease on or after the last prior therapy, or participants who were intolerant to the last prior therapy. * Measurable disease, as defined by the protocol * Participants agree to follow contraception or abstinence requirements as defined in the protocol Exclusion Criteria: * Any anti-cancer therapy within 3 weeks prior to initiation of study treatment with exception defined by the protocol * Participants with autologous stem cell transplantation (SCT) within 100 days prior to first dose of study treatment * Participants with prior allogeneic SCT or solid organ transplantation * Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) * Active or history of autoimmune disease * Participants with current or history of Central Nervous System (CNS) disease, or current CNS involvement by Multiple Myeloma (MM) * Significant cardiovascular disease * Participants with known clinically significant liver disease * Symptomatic active pulmonary disease requiring supplemental oxygen * Known active infection requiring intravenous anti-microbial therapy within 14 days prior to first study drug administration * Any episode of active, symptomatic COVID-19 infection, or requiring treatment with IV antivirals for COVID-19 (not including COVID-19 primary prophylaxis) within 14 days, prior to first study treatment * Other protocol defined inclusion/exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • Alfred Hospital

    Melbourne, Victoria, 3004, Australia

  • Asan Medical Center - PPDS

    Seoul, 05505, South Korea

  • Clinica Universidad de Navarra

    Pamplona, Navarre, 31008, Spain

  • Evangelismos General Hospital of Athens

    Athens, 106 76, Greece

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, 46026, Spain

  • Oslo University Hospital Rikshospitalet

    Oslo, N - 0424, Norway

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Rabin Medical Center-Beilinson Campus

    Petah Tikva, 4941492, Israel

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000, Australia

  • Severance Hospital, Yonsei University

    Seoul, 03722, South Korea

  • Sygehus Lillebaelt - Vejle Sygehus

    Vejle, 7100, Denmark

  • Tel Aviv Sourasky Medical Center PPDS

    Tel Aviv, 64239, Israel

  • University of Athens, Hematological Clinic,

    Athens, 115 28, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.